Tech Center 1600 • Art Units: 1634 1682
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17998051 | LIQUID BIOPSY PLATFORM IN PLASMA AND SALIVA | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18329972 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR IL-33-MEDIATED DISORDERS | Non-Final OA | Genentech, Inc. |
| 17596821 | Diagnostics and Treatments Based Upon Molecular Characterization of Colorectal Cancer | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17813193 | ncRNA AND USES THEREOF | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18025365 | METHODS OF DETECTING AN INACTIVATING MUTATION OF PBRM1 IN MENINGIOMA | Non-Final OA | Foundation Medicine, Inc. |
| 18534101 | IMPROVED METHODS TO DIAGNOSE HEAD AND NECK CANCER AND USES THEREOF | Non-Final OA | The University of North Carolina at Chapel Hill |
| 17301187 | BIOMARKERS FOR ASSESSING IDIOPATHIC PULMONARY FIBROSIS | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18631414 | METHODS FOR PREDICTING RISK OF INTERSTITIAL PNEUMONIA | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 17416988 | BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER | Non-Final OA | UNIVERSITÉ DE MONTPELLIER |
| 18538995 | TISSUE-SPECIFIC METHYLATION MARKER | Final Rejection | GRAIL, LLC |
| 16921287 | METHODS OF PREDICTING PREDISPOSITION TO OR RISK OF KIDNEY DISEASE | Non-Final OA | Wake Forest University Health Sciences |
| 17325839 | RAPID DIAGNOSTIC SYSTEM USING TARGETED ANTISENSE OLIGONUCLEOTIDE CAPPED PLASMONIC NANOPARTICLES | Non-Final OA | University of Maryland, Baltimore County |
| 16864125 | FRATAXIN-SENSITIVE MARKERS FOR DETERMINING EFFECTIVENESS OF FRATAXIN REPLACEMENT THERAPY | Final Rejection | Larimar Therapeutics, Inc. |
| 16760522 | CANCER DETECTION, CLASSIFICATION, PROGNOSTICATION, THERAPY PREDICTION AND THERAPY MONITORING USING METHYLOME ANALYSIS | Final Rejection | SINAI HEALTH SYSTEM |
| 17237789 | QUANTITATIVE DETECTION OF MICRO-RNAS | Final Rejection | GENFIT |
| 18160366 | METHOD AND SYSTEM OF DIAGNOSING AND TREATING NEURODEGENERATIVE DISEASE AND SEIZURES | Non-Final OA | MOREHOUSE SCHOOL OF MEDICINE |
| 18351274 | PREDICTING PEPTIDE RECEPTOR RADIOTHERAPY USING A GENE EXPRESSION ASSAY | Final Rejection | Liquid Biopsy Research LLC |
| 16990572 | DNA METHYLATION BIOMARKERS OF POST-PARTUM DEPRESSION RISK | Non-Final OA | UNIVERSITY OF MARYLAND |
| 16562861 | DIAGNOSTIC AND PROGNOSTIC LIQUID BIOPSY BIOMARKERS FOR ASTHMA | Non-Final OA | University of Sharjah |
| 18030515 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER OR COLORECTAL ADENOMA BY USING CPG METHYLATION CHANGE OF LINC01798 GENE, AND USE THEREOF | Non-Final OA | GENCURIX INC. |
| 18247840 | METHOD FOR DIAGNOSING STROKE UTILIZING GENE EXPRESSION SIGNATURES | Non-Final OA | Ischemia Care LLC |
| 18004030 | METHYLATED MARKERS FOR ACCURATE DETECTION OF PRIMARY CENTRAL NERVOUS SYSTEM AND SYSTEMIC DIFFUSE LARGE B CELL LYMPHOMA | Non-Final OA | RENMIN HOSPITAL OF WUHAN UNIVERSITY |
| 18014053 | IMMUNE PROFILING AND METHODS OF USING SAME TO PREDICT RESPONSIVENESS TO AN IMMUNOTHERAPY AND TREAT CANCER | Non-Final OA | GoPath Laboratories LLC |
| 18088405 | METHOD FOR SORTING COLORECTAL CANCER AND ADVANCED ADENOMA AND USE OF THE SAME | Non-Final OA | INOGENIX Inc. |
| 17290061 | Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies | Non-Final OA | Nottingham Trent University |
| 18008100 | COMBINATION OF GENE MARKERS AND USE THEREOF | Non-Final OA | CREATIVE, BIOSCIENCES (GUANGZHOU)CO., LTD. |
| 17996267 | FMT PERFORMANCE PREDICTION TEST TO GUIDE AND OPTIMIZE THERAPEUTIC MANAGEMENT OF GVHD PATIENTS | Non-Final OA | MaaT PHARMA |
| 16284963 | PROSTATE CANCER ASSOCIATED CIRCULATING NUCLEIC ACID BIOMARKERS | Non-Final OA | CHRONIX BIOMEDICAL |
| 17929881 | CANCER BIOMARKERS AND CLASSIFIERS AND USES THEREOF | Final Rejection | Veracyte SD, Inc. |
| 17773273 | METHODS OF ANALYZING A BIOLOGICAL SAMPLE | Final Rejection | Wallac Oy |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy